Gadavist

PreclinicalSmall molecule

UUniversity of California, San Francisco

Gadavist is one of 2 small molecule programs targeting Ischemic Heart Disease (IHD). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ischemic Heart Disease (IHD)Recruiting

Ischemic Heart Disease (IHD)Preclinical

Recruiting

Competition

Competitive Landscape

2 competitors in Ischemic Heart Disease (IHD)

#DrugCompanyPhaseTrials

Gadavist

UUniversity of California, San Francisco

Preclinical

1 2

Vasodilator

IIndiana University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

PreclinicalRecruiting

Ischemic Heart Disease (IHD)

NCT06854458

Q3 2029

N/ANot yet recruiting

Leptomeningeal Disease

NCT07415018

Clinical

Trials by Indication[1]

Leptomeningeal Disease1 trial

Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease

Not yet recruiting·MM.D. Anderson Cancer Center·N/A·NCT07415018·40 enrolled

Ductal Carcinoma in Situ1 trial

Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)

Completed·UUniversity of California, San Francisco··NCT00804128·76 enrolled

Ischemic Heart Disease (IHD)1 trial

The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States (SPINS2) Study

Recruiting·BBrigham and Women's Hospital·Preclinical·NCT06854458·1,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Gadavist. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gadavist compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gadavist. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Francisco company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of California, San Francisco

Gadavist

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q3 2029

Trials by Indication[1]

Leptomeningeal Disease1 trial

Ductal Carcinoma in Situ1 trial

Ischemic Heart Disease (IHD)1 trial

References

Drug Info

Quick Facts

Related News